Diependeek Facility: AAALAC International accreditation
InnoSer proudly announces that its preclinical service facility in Diepenbeek, Belgium, has been granted full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. This landmark demonstrates the continuous progress towards the company’s goal to have all sites accredited by AAALAC.
Leiden Facility: AAALAC international accreditation
In June 2019 the Leiden facility was re-audited by AAALAC and InnoSer is delighted to share that the AAALAC certification is extended.
To support the achievements in Leiden and Diepenbeek, InnoSer has made targeted investments in people, processes and facilities that will help to ensure the quality of its preclinical services.
Jan Bartels, Chief Executive Officer commented: "The AAALAC accreditation of Diepenbeek and the extension of the AAALAC certification in Leiden is great news and demonstrates the high standards we set for animal welfare and health & safety at InnoSer. Our management and staff are delighted with this important milestone. This is highly appreciated by our clients who continuously work closely with us in developing medicines for life threatening diseases."
Business Development Manager
Per August 1st, 2019 Erik Jans will join the InnoSer team as Business Development Manager
Erik obtained his Master degree in Molecular Biology at the Free University of Brussels in 1992. Following an additional Master Program in Medical & Pharmaceutical Drug Development in 1998-1999 he started working in Life Science companies, in various Sales & Marketing functions and Management.
Throughout his career Erik has worked extensively in cell biology and Immunology, with a focus on extracellular and intracellular signaling/communication pathways. In recent years he supported Pharma & Biotech companies on the European continent in their preclinical work on Immuno-oncology, Biologics, Gene Therapy and Cell Therapy.
Erik is looking forward to work with all InnoSer prospects and customers.